A First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

Healthy Volunteers Clinical Trial

Official title:

A First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of GUB014295 in Lean to Overweight or Obese But Otherwise Healthy Men

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06144684
• Other study ID #: GUC17-01
• Secondary ID: 1008236
• Status: Recruiting
• Phase: Phase 1
• Start date: November 29, 2023
• Est. completion date: December 2024

Study information

• Verified date: November 2023
• Source: Gubra A/S
• Contact: Gubra
• Phone: +45 31522650
• Email: info[@]gubra.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, double-blind, randomized, placebo-controlled, single ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men. It is planned to enroll 4 cohorts of 8 subjects (Regimens A, B, C and D), with 2 additional optional cohorts of 8 subjects (Regimens E and F). Within each cohort, subjects will be randomized in a ratio of 6 active to 2 placebo. The primary objective is to assess the safety. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate pharmacodynamic effects.

Description:

This is a first in human clinical trial assessing a single dose of a new long-acting amylin analogue GUB014295.

Trial design: This is a single center, double-blind, randomized, placebo-controlled, single ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men. It is planned to enroll 4 cohorts of 8 subjects (Regimens A, B, C and D), with 2 additional optional cohorts of 8 subjects (Regimens E and F). Within each cohort, subjects will be randomized in a ratio of 6 active to 2 placebo. The primary objective is to assess the safety of a new long-acting amylin-analogue GUB014295. Secondary objectives are to characterize the pharmacokinetics (PK) of the long-acting amylin-analogue GUB014295 and to investigate if the long-acting amylin-analogue GUB014295 has possible pharmacodynamic effects measured as weight changes and changes in gastric emptying (paracetamol concentration) and changes in glucose, insulin, C-peptide, and glucagon during a mixed meal test.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: December 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Lean to overweight or obese but otherwise healthy males

• BMI of 22.0 to 32.0 kg/m2 as measured at screening.

• Overweight or obese as assessed by BMI should be due to excess adipose tissue, as judged by the investigator

• Weight =70 kg at screening

Exclusion Criteria:

• Medical/Surgical History and Mental Health

• Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients

• Presence or history of clinically significant allergy requiring treatment, as judged by the investigator.

• Hay fever is allowed unless it is active

• Known or suspected hypersensitivity or allergy to paracetamol

• Presence or history of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric, malignant, metabolic, endocrinological, haematological or venereal disorder, as judged by the investigator

• Presence or history of any clinically relevant gastrointestinal diseases or symptoms of gastrointestinal disorders potentially affecting interpretation of study data.

• Presence or history of diseases associated with impaired calcium homeostasis and/or increased bone turnover (e.g. Paget´s disease, osteoporosis)

• History of major depressive disorder within 2 years prior to screening

• Subjects unable to take paracetamol for any reason

• Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening

• Subjects with tattoos or scars on the abdomen which may interfere with injection site assessments as determined by the investigator or delegate at screening

• Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis as judged by the investigator .

• Subjects with Gilbert's Syndrome are not allowed.

• HbA1c =48 mmol/mol (=6.5%) and/or fasting plasma glucose =7.0 mmol/L at screening

• Prolongation of the QTcF over 450 msec or any other clinically significant abnormal ECG results as judged by the investigator

• Supine blood pressure (after =5 min rest) <90 mmHg or >150 mmHg (systolic) and/or <50 mmHg or >90 mmHg (diastolic)

• Heart rate (ECG-recorded after =5 min rest) <45 or >90 beats per minute

• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results

• Evidence of renal impairment at screening, as indicated by an estimated glomerular filtration rate (eGFR) of <80 mL/min/1.73m2

• Subjects who have received any investigational medicinal product (IMP) in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer

• Subjects who have previously been administered IMP in this study

• Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood

• Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies/vitamins in the 14 days before IMP administration.

• Paracetamol (up to 4 g per day) will be permitted except in the 48 h prior to the mixed meal tests on Day -1 and Day 4 for Cohorts 2 to 6 where paracetamol is not permitted.

• NSAIDs can be given at the discretion of the investigator to treat any AEs if necessary;

• Subject reports prior receipt of an amylin and/or calcitonin receptor agonist within the last 6 months

• History of any drug or alcohol abuse in the past 2 years

• Regular alcohol consumption >21 units per week

• A confirmed positive alcohol breath test at screening or admission

• Current smokers and those who have smoked within the last 12 months

• Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

• A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission

• Confirmed positive drugs of abuse test result at screening or admission

• Anticipated change in lifestyle (such as eating, exercise or sleeping pattern) during the trial and/or clinically significant body weight change (=5% self-reported change) or comprehensive dieting attempts (e.g. participation in a weight reduction program or treatment with any medication indicated for weight management) within the last 90 days prior to screening

• Subjects who do not agree to consume the liquid mixed meal

• Male subjects with pregnant or lactating partners

• Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria, that the investigator evaluates might jeopardise the subject's safety or compliance with the protocol

Related Conditions & MeSH terms

• Healthy Volunteers
• Overweight

Intervention

Drug:
• GUB014295
GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered.
• GUB014295-PLACEBO
GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered.

Locations

Country	Name	City	State
United Kingdom	Quotient Sciences	Nottingham

Sponsors (2)

Lead Sponsor	Collaborator
Gubra A/S	Quotient Sciences

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacodynamic - body weight	Change in body weight (kg) from baseline to the end of the study. Descriptive summary for pharmacodynamic data (weight) including changes from baseline will be provided by all placebo and each active treatment.	from baseline (day 0) until end of trial (day 29) and until follow up (day 43)
Other	Pharmacodynamic - liquid meal test incl. paracetamol (cohort 2-6 only)	To investigate change in plasma concentration of glucose, insulin, C-peptide, glucagon and paracetamol in a paired liquid mixed meal test before (day-1) and after dosing (day4) of a single dose of GUB014295. Descriptive summary (as a relative change (ratio: 0 - 1) from day -1 to day 4) for all pharmacodynamic data (glucose, insulin, C-peptide, glucagon and paracetamol) will be provided by all placebo and each active treatment.	before dosing (day -1) and day 4
Primary	Safety - Adverse Events (AE) incidence	To provide safety information for GUB014295 by assessing: incidence of AEs categorized in System Organ Class (SOC) according to MedDRA (and evaluating severity and duration for SOC). No formal hypothesis will be tested in the study. Descriptive summaries for all safety safety data for all placebo, each active treatment and all active will be provided (including changes from baseline)	from baseline (day 0) to end of trial (day 29)
Primary	Safety - changes in vital signs	To provide safety information for GUB014295 by assessing: Any changes from baseline for vital signs including: Blood pressure, Pulse/heart rate, oral temperature and respiratory frequency summarized as a ratio (baseline/day 29).; No formal hypothesis will be tested in the study. Descriptive summaries (as a relative change (ratio: 0 - 1) from day 0 to day 29) for all safety safety data for all placebo, each active treatment and all active will be provided.	from baseline (day 0) to end of trial (day 29)
Primary	Safety - Safety laboratory parameters	To provide safety information for GUB014295 by assessing a wide range of laboratory parameters within hematology, coagulation, clinical chemistry, virology, urinalysis.; No formal hypothesis will be tested in the study. Descriptive summaries (as a relative change (ratio: 0 - 1) from day 0 to day 29)) for all safety safety data for all placebo, each active treatment and all active will be provided.	from baseline (day 0) to end of trial (day 29)
Secondary	Pharmacokinetic (PK) - Tmax and Cmax	PK parameters: Tmax, (time of observed maximum concentration), Cmax (maximum observed concentration), for GUB014295.	from dosing (day 0) until maximum concentration (estimated day 4)
Secondary	Pharmacokinetic (PK) - area under the concentration curve (AUC)	PK parameters: AUC(0-72) area under the curve for the GUB014295 measured from dosing, until 72 hours post dose, AUC(0-168) area under the curve for the GUB014295 measured from dosing, until 168 hours post dose, AUC(0-last) area under the curve for the GUB014295 measured from dosing, until the time of last measurable concentration, AUC(0-inf) area under the curve for the GUB014295 concentration from dosing, extrapolated until infinity.	from dosing (day 0) until end of trial (day 29)
Secondary	Pharmacokinetic (PK) - T1/2	PK parameters: T1/2: Terminal elimination half-life,	from dosing (day 0) until end of trial (day 29)
Secondary	Pharmacokinetic (PK) - CL/F	PK parameters: CL/F: Total body clearance (CL) calculated after single subcutaneous administration where F (fraction of bioavailability) is unknown,	from dosing (day 0) until end of trial (day 29)
Secondary	Pharmacokinetic (PK) - Vz/F	PK parameters: Vz/F: apparent volume of distribution (Vz) based on terminal phase calculated using AUC(0-inf) after a single subcutaneous administration where F (fraction of bioavailability) is unknown,	from dosing (day 0) until end of trial (day 29)